Effect of chronic pre-treatment with angiotensin converting enzyme inhibition on skeletal muscle mitochondrial recovery after ischemia/reperfusion

Fundamental and Clinical Pharmacology

Volumn 24, Issue 3, 2010, Pages 333-340

  Thaveau, Fabien ^a   Zoll, Joffrey ^a,b   Bouitbir, Jamal ^a,b   N'Guessan, Benoît ^b   Plobner, Philippe ^b   Chakfe, Nabil ^a   Kretz, Jean Georges ^a   Richard, Ruddy ^a,b   Piquard, François ^a,b   Geny, Bernard ^a,b  

^a HÔPITAL CIVIL   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

ACE inhibition; Ischemia reperfusion; Mitochondria; Muscle; Peripheral arterial disease; Renin angiotensin

Indexed keywords

ASCORBIC ACID; CAPTOPRIL; CYTOCHROME C OXIDASE; GLUTAMIC ACID; MALIC ACID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SUCCINATE DEHYDROGENASE (UBIQUINONE); SUCCINIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROCNEMIUS MUSCLE; LEG ISCHEMIA; LEG REVASCULARIZATION; MALE; MITOCHONDRIAL ENERGY TRANSFER; MITOCHONDRIAL RESPIRATION; NONHUMAN; OXIDATION; PRIORITY JOURNAL; RAT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DRUG ADMINISTRATION SCHEDULE; ELECTRON TRANSPORT; HINDLIMB; MALE; MITOCHONDRIA, MUSCLE; MUSCLE, SKELETAL; NEURAL INHIBITION; RATS; RATS, WISTAR; RECOVERY OF FUNCTION; REPERFUSION INJURY; TIME FACTORS; TREATMENT OUTCOME;

EID: 77952580094     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2009.00763.x     Document Type: Article

References (37)

1. Bell P. The management of lower limb ischemia. J. Cardiovasc. Surg. (2008) 49 141 143. (Pubitemid 351833232)
2. Miller C.C. III., Villa M.A., Achouh P., et al. Intraoperative skeletal muscle ischemia contributes to risk of renal dysfunction following thoracoabdominal aortic repair. Eur. J. Cardiothorac. Surg. (2008) 33 691 694.
3. Brandao M.L., Roselino J.E., Piccinato C.E., Cherri J. Mitochondrial alterations in skeletal muscle submitted to total ischemia. J. Surg. Res. (2003) 110 235 240. (Pubitemid 36403714)
4. Grisotto P.C., Dos Santos A.C., Coutinho-Netto J., Cherri J., Piccinato C.E. Indicators of oxidative injury and alterations of the cell membrane in the skeletal muscle of rats submitted to ischemia and reperfusion. J. Surg. Res. (2000) 9 1 6. (Pubitemid 30437450)
5. Pipinos I.I., Judge A.R., Zhu Z., et al. Mitochondrial defects and oxidative damage in patients with peripheral arterial disease. Free Radic. Biol. Med. (2006) 41 262 269. (Pubitemid 43928501)
6. Lagouge M., Argmann C., Gergart-Hines Z., et al. Resveratrol improves mitochondrial function and protects against metabolic diseases by activating SIRTI and PGC-1alpha. Cell (2006) 217 1 14.
7. Zoll J., Sanchez H., N'Guessan B., Ribera F., Lampert E., Bigard X. Physical activity changes the regulation of mitochondrial respiration in human skeletal muscle. J. Physiol. (2002) 543 191 200. (Pubitemid 34947306)
8. Pipinos I.I., Boska M.D., Shepard A.D., Anagnostopoulos P.V., Katsamouris A. Pentoxifylline reverses oxidative mitochondrial defect in claudicating skeletal muscle. J. Surg. Res. (2002) 102 126 132. (Pubitemid 34969457)
9. Thaveau F., Zoll J., Rouyer O., et al. Ischemic preconditioning spicifically restores complexes I and II activities of the mitochondrial respiratory chain in ischemic skeletal muscle. J. Vasc. Surg. (2007) 92 1047 1056.
10. McAllister S.E., Ashrafpour H., Cahoon N., et al. Postconditioning for salvage of ischemic skeletal muscle from reperfusion injury: efficacy and mechanism. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2008) 295 681 689.
11. Rehring T.F., Stolcpart R.S., Whitton Hollis H. Jr. Pharmacologic risk factor management in peripheral arterial disease: a vade mecum for vascular surgeons. J. Vasc. Surg. (2008) 47 1108 1115.
12. Rice T.W., Lumsden A.B. Optimal medical management of peripheral arterial disease. Vasc. Endovascular. Surg. (2006) 40 312 327. (Pubitemid 44450494)
13. Ahimastos A.A., Lawler A., Reid C., Blombery P.A., Kingwell B.A. Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease. A randomized trial. Ann. Intern. Med. (2006) 144 660 664. (Pubitemid 46780650)
14. Onder G., Vedova C.D., Pahor M. Effects of ACE inhibitors on skeletal muscle. Curr. Pharm. Des. (2006) 12 2057 2064. (Pubitemid 43821692)
15. Minami N., Guo O., Kawara T., et al. Effect of angiotensin-converting enzyme inhibitor and exercises training on exercise capacity and skeletal muscle. J. Hypertens. (2007) 25 1241 1248. (Pubitemid 46918803)
16. Dragović T., Minshall R., Jackman H.L., Wang L.X., Erdös E.G. Kininase II-type enzymes. Their putative role in muscle energy metabolism. Diabetes (1996) 45 34 37.
17. Vicaut E., Hou X. Arteriolar constriction and local renin-angiotensin system in rat microcirculation. Hypertension (1993) 21 491 497. (Pubitemid 23095163)
18. Linderman J.R., Greene A.S. Distribution of angiotensin II receptor expression in the microcirculation of striated muscle. Microcirculation (2001) 8 275 281.
19. Jones A., Wood D.R. Skeletal muscle RAS and exercise performance. Int. J. Biochem. Cell Biol. (2003) 35 855 866. (Pubitemid 36379327)
20. Müller M., Fasching P., Schmid R., Burgdorff T., Waldhäusl W., Eichler H.G. Inhibition of paracrine angiotensin-converting enzyme in vivo: effects on interstitial glucose and lactate concentrations in human skeletal muscle. Eur. J. Clin. Invest. (1997) 27 825 830. (Pubitemid 27460618)
21. Cahova M., Vavrinkova H., Tutterova M., Meschisvilli E., Kazdova L. Captopril enhanced insulin-stimulated glycogen synthesis in skeletal muscle but not fatty acid synthesis in adipose tissue of hereditary hypertriglyceridemic rats. Metabolism (2003) 52 1406 1412. (Pubitemid 37474026)
22. Henriksen E.J., Jacob S. Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition. J. Cell Physiol. (2003) 196 171 179. (Pubitemid 36676455)
23. Wan P., Fedoruk M.N., Rupert J.L. Keeping Pace with ACE. Sports Med. (2008) 38 1065 1079.
24. Zoll J., Monassier L., Garnier A., et al. ACE inhibition prevents myocardial infarction-induced skeletal muscle mitochondrial dysfunction. J. Appl. Physiol. (2006) 101 385 391. (Pubitemid 44162345)
25. Thaveau F., Zoll J., Bouitbir J., et al. Contralateral leg as a control during skeletal muscle ischemia-reperfusion. J. Surg. Res. (2009) 24 472 474.
26. Gupta K., Aggarwal N., Rao M., Verma U.C., Anand R. Re-emphasizing the importance of tourniquet time: severe myocardial depression following tourniquet deflation. Acta Anaesthesiol. Scand. (2008) 52 873. (Pubitemid 351829485)
27. Anderson E.J., Neufer P.D. Type II skeletal myofibers possess unique properties that potentiate mitochondrial H(2)O(2) generation. Am. J. Physiol. Cell Physiol. (2006) 290 C844 C851.
28. Ambrosio G., Zweier J.L., Flaherty J.T. The relationship between oxygen radical generation and impairment of myocardial energy metabolism following post-ischemic reperfusion. J. Mol. Cell Cardiol. (1991) 23 1359 1374.
29. Marktanner R., Nacke P., Feindt P., Hohlfeld T., Schipke J.D., Gams E. Delayed preconditioning via Angiotensin-converting enzyme inhibition: pros and cons from an experimental study. Clin. Exp. Pharmacol. Physiol. (2006) 33 787 792. (Pubitemid 44215130)
30. Emanueli C., Salis M.B., Stacca T., et al. Ramipril improves hemodynamic recovery but not microvascular response to ischemia in spontaneously hypertensive rats. Am. J. Hypertens. (2002) 15 410 415. (Pubitemid 34478480)
31. Van de Ven L.L., Van Leeuwen J.T., Smit A.J. The influence of chronic treatment with betablockade and angiotensin converting enzyme inhibition on the peripheral blood flow in hypertensive patients with and without concomitant intermittent claudication. A comparative cross-over trial. Vasa (1994) 23 357 362.
32. Zoll J., N'Guessan B., Ribera F., et al. Preserved response of mitochondrial function to short-term endurance training in skeletal muscle of heart transplant recipients. J. Am. Coll. Cardiol. (2003) 42 126 132. (Pubitemid 36760773)
33. Momken I., Kahapip J., Bahi L., et al. Does angiotensin-converting enzyme inhibition improve the energetic status of cardiac and skeletal muscles in heart failure induced by aortic stenosis in rats? J. Mol. Cell Cardiol. (2003) 35 399 407. (Pubitemid 36411701)
34. Rouyer O., Zoll J., Daussin F., et al. Muscle: effect of angiotensin-converting enzyme inhibition on skeletal muscle oxidative function and exercise capacity in streptozotocin-induced diabetic rats. Exp. Physiol. (2007) 92 1047 1056. (Pubitemid 47568841)
35. Silvestre J.S., Kamsu-Kom N., Clergue M., Duriez M., Lévy B.I. Very-low-dose combination of the angiotensin-converting enzyme inhibitor perindopril and the diuretic indapamide induces an early and sustained increase in neovascularization in rat ischemic legs. J. Pharmacol. Exp. Ther. (2002) 303 1038 1043. (Pubitemid 35424387)
36. Migdalof B.H., Antonaccio M.J., McKinstry D.N., et al. Captopril: pharmacology, metabolism and disposition. Drug Metab. Rev. (1984) 15 841 869.
37. Kunori Y., Muroga Y., Iidaka M., Mitsuhashi H., Kamimura T., Fukamizu A. Species differences in angiotensin II generation and degradation by mast cell chymases. J. Recept. Signal Transduct. Res. (2005) 25 35 44. (Pubitemid 40780996)